Nonvitamin K antagonist oral anticoagulants have advantages compared with warfarin, but both types of anticoagulants come with uncertainty about how best to manage life-threatening bleeding events, urgent surgeries, and invasive procedures. Nurse practitioners and physician assistants may need to manage such emergency situations in the critical care setting. Achieving hemostasis quickly is key, and efforts to do so have relied mainly on blood products. Targeted reversal agents are in clinical development and one, idarucizumab, which reverses dabigatran anticoagulation, has been approved. Current options for managing events and urgent procedures in anticoagulated patients are discussed in this article, with a focus on specific reversal agents.
Skip Nav Destination
Article navigation
Winter 2017
Feature|
December 15 2017
Reversal Strategies for Newer Oral Anticoagulants
Adam J. Singer, MD;
Adam J. Singer, MD
Adam J. Singer is Professor and Vice Chairman for Research, Department of Emergency Medicine, Stony Brook University Hospital, Stony Brook, NY 11794-8350 ([email protected]). Susan Wilson is Associate Professor, Department of Neurology, and Adult Stroke Nurse Practitioner, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Search for other works by this author on:
Susan Wilson, RN, MSN, C-ANP
Susan Wilson, RN, MSN, C-ANP
Adam J. Singer is Professor and Vice Chairman for Research, Department of Emergency Medicine, Stony Brook University Hospital, Stony Brook, NY 11794-8350 ([email protected]). Susan Wilson is Associate Professor, Department of Neurology, and Adult Stroke Nurse Practitioner, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Search for other works by this author on:
AACN Adv Crit Care (2017) 28 (4): 322–331.
Citation
Adam J. Singer, Susan Wilson; Reversal Strategies for Newer Oral Anticoagulants. AACN Adv Crit Care 15 December 2017; 28 (4): 322–331. doi: https://doi.org/10.4037/aacnacc2017744
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access